{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:58:50Z","timestamp":1772751530846,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Hypoparathyroidism is a rare endocrine disorder characterized by low or insufficient parathyroid hormone (PTH) concentrations leading to hypocalcemia, hyperphosphatemia, and markedly reduced bone turnover. Despite being a rare disease, hypoparathyroidism has a profound impact on affected patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent epidemiologic surveys demonstrate a prevalence of between 5.3 and 40\/100\u200a000, confirming the orphan status of this disease. There is a female predominance, and anterior neck surgery is the most common etiology. Recent studies have better elucidated the chronic manifestations of the disease, impacting quality of life and multiple organ systems including the renal, cardiovascular, and skeletal systems. There are now data on longer term use of parathyroid hormone (PTH) and PTH analogs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>This review focuses on recent contributions to the literature on the prevalence and epidemiology of the disease, risk of chronic manifestations, and treatment with PTH(1-34) and rhPTH(1-84). Further research is needed to determine the pathophysiology of complications in hypoparathyroidism and whether interventions can decrease future risk of these complications. In addition, further data are needed with regards to more physiologic dosing regimens and long-term treatment with PTH and PTH analogs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000618","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T23:03:43Z","timestamp":1558134223000},"page":"381-387","source":"Crossref","is-referenced-by-count":12,"title":["Update on hypoparathyroidism"],"prefix":"10.1097","volume":"31","author":[{"given":"Natalie E.","family":"Cusano","sequence":"first","affiliation":[{"name":"Bone Metabolism Program, Division of Endocrinology, Department of Medicine, Lenox Hill Hospital and Zucker School of Medicine at Hofstra\/Northwell"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"International Education and Research, Emeritus, Division of Endocrinology, Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and incidence of hypoparathyroidism in the United States using a large claims database","volume":"28","author":"Powers","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R2-20230829","first-page":"S182","article-title":"Co-morbid-medical conditions associated with prevalent hypoparathyroidism: a population-based study","volume":"26","author":"Clarke","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jbmr.3329","article-title":"A population-based study of the epidemiology of chronic hypoparathyroidism","volume":"33","author":"Vadiveloo","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00223-016-0222-7","article-title":"The epidemiology of hypoparathyroidism in Italy: an 8-year register-based study","volume":"100","author":"Cipriani","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00223-018-0405-5","article-title":"Prevalence of chronic hypoparathyroidism in a Mediterra nean region as estimated by the analysis of Anonymous Healthcare Database","volume":"103","author":"Cianferotti","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/EJE-18-0580","article-title":"Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study","volume":"180","author":"David","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cen.13895","article-title":"Increased mortality and morbidity in patients with chronic hypoparathyroidism: a population-based study","volume":"90","author":"Vadiveloo","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/jc.2018-02228","article-title":"Auditing the efficacy and safety of alfacalcidol and calcium therapy in idiopathic hypoparathyroidism","volume":"104","author":"Saha","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"106","DOI":"10.20945\/2359-3997000000015","article-title":"Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism","volume":"62","author":"Maeda","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/cen.13927","article-title":"Cardiovascular findings in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism: a cohort study","volume":"90","author":"Underbjerg","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/jbmr.2812","article-title":"Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism","volume":"31","author":"Sikjaer","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1074\/jbc.270.26.15455","article-title":"Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor","volume":"270","author":"Usdin","year":"1995","journal-title":"J Biol Chem"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1210\/jc.2017-02593","article-title":"Does PTH replacement therapy improve quality of life in patients with chronic hypoparathyroidism?","volume":"103","author":"Winer","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20230829","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02430","article-title":"Quality of life in hypoparathyroidism improves with rhPTH(1-84) throughout 8 years of therapy","author":"Tabacco","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-13-1","article-title":"Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density","volume":"13","author":"Mendonca","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"R33-20230829","first-page":"251","article-title":"Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up","volume":"102","author":"Chawla","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jbmr.3543","article-title":"The effects of long-term administration of rhPTH(1-84) in hypoparathyroidism by bone histomorphometry","volume":"33","author":"Rubin","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-20230829","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"556.e1","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"R43-20230829","first-page":"G174","article-title":"The design and preliminary results of a phase 1 TransCon PTH trial in healthy volunteers","volume":"56","author":"Karpf","year":"2018","journal-title":"Endocrine Abstr"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:41:30Z","timestamp":1693291290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000618","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}